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OBJECTIVES: Decisions about the use of new medical technologies based on esti-
mates of the average cost-effectiveness across a potentially heterogeneous popu-
lation runs the risk of foregoing net health benefits(NHB) for sub-groups of the
population. We propose a general framework within which to assess between-
patient heterogeneity and its role in cost-effectiveness subgroup analysis(CESA),
complementing this with a practical application.METHODS:We first describe how
to extend methods for cost-effectiveness analysis (based on current information)
to address issues such as estimation of NHB, sources of heterogeneity, definition
and selection of subgroups. Next, we define the role of uncertainty in CESA, ex-
tending the concept of Value of Information(VoI) to include the notion of a static
and dynamic Value of Heterogeneity(VoH). The application of the proposed theoret-
ical framework is illustrated using a cost-effectiveness model developed for the
analysis of a multicentre-trial(RITA-3), which assessed the efficacy of an early ar-
teriography with revascularisation versus standard management in patients with
acute coronary-syndrome. Using this model we conducted a re-analysis investi-
gating alternative subgroup specifications, varying between one and five sub-
groups, with a view to produce an efficiency frontier for subgroup analysis relating
to this decision problem. We assessed the static and dynamic VoH under each
specification. RESULTS: The population expected NHB when considering five sub-
groups was 105,500 QALYs greater than decision based on estimates for the average
population (static-VoH). Although, identifying 5 subgroups reduced in the Expected
Value of Perfect Information(EVPI) (920 QALYs, at a threshold of £30,000/QALY), the
potential NHB from resolving uncertainty was greater after heterogeneity has been
identified (dynamic-VoH). CONCLUSIONS: Our initial findings support the argu-
ment that explicit consideration of heterogeneity in CEA leads to a positive static
and dynamic VoH. In addition, heterogeneity not only may increase the EVPI but
can also reduce its magnitude. The VoH framework offers a useful guidance for a
more systematic CESA.
PODIUM SESSION III:
TOWARDS A BETTER UNDERSTANDING OF REIMBURSEMENT DECISIONS
BASED ON HTA ARGUMENTS
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OBJECTIVES: The European Transparency Directive 89/105 (TD) imposes the use of
objective and verifiable criteria in national pharmaceutical reimbursement deci-
sions: for pharmaceuticals claiming added therapeutic value (ATV), the Belgian
DRD uses 5 criteria comparing the product to its alternatives: effectiveness, effi-
ciency, price, budget impact and therapeutic need . The study aim was to analyze
the effect significance and size on the (yes/no) DRD of a set of parameters including:
added therapeutic value ATV (yes/no), trial end-points (clinical or surrogate), level
of evidence (RCT yes or no), availability of alternatives (yes/no), ICER and budget
impact (in K Euro) in order to estimate the percentage of variability in DRD that
could be explained by these explicit factors.METHODS: The National Health Insur-
ance administrative database was used for extracting all publicly available DRDs
on products claiming ATV submitted between 2002 and 2007. Data retrieval was
substantially extended compared to previous work. ICERs expressed per QALY or
per LYG were pooled. Logistic regression was performed using SPSS 15.0. The sig-
nificance level was set at 0.05. RESULTS: A total of 110 submissions were retrieved:
40% had complete records. The regression analysis yielded a significant model (p
0.01) with 58% of the variance explained and only 3 significant factors: ATV (p 
0.001), budget impact estimate (p  0.05) and the computed ICER (p  0.05). Higher
estimates of budget impact and ICER decreased the probability of a positive DRD.
No significant interactions were observed (p  0.10). CONCLUSIONS: Multivariate
analyses identified granting of ATV, pharmaceutical budget impact and the eco-
nomic ICER to significantly affect the DRD. These 3 factors are among the 5 criteria
on which the DRD should be based. Because of missing data some caution is needed
on these inferences. Systematic public reporting of key submitted data would in-
crease the feasibility of powerful analyses enhancing transparency.
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VALUE BASED PRICING: ONE THRESHOLD TOO FAR FOR THE UNITED KINGDOM
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ISSUE: The budget for the NHS in England is declining in real terms by around 2%
per year. Despite productivity having fallen in recent years, the NHS expected to
make efficiency savings of between £15 and 20bn over the next 3 years. Will the
proposed implementation of value based pricing (VBP) help or hinder the pursuit of
a more efficient NHS.OVERVIEW:The objectives for implementing VBP and replac-
ing the PPRS in the UK are to encourage innovation where there is unmet need,
improve outcomes and ensuring value for money to the NHS with better access to
effective medicines. Different willingness to pay thresholds are suggested as a way
to incorporate these societal benefits when setting the price of a new pharmaceu-
tical. Using this mechanism to incentivise pharma could be profitable for the in-
dustry with the unintended outcome of decreasing efficiency in the heath service
at a time when it is not affordable. Let’s consider two ‘innovative’ products (A and
B) and assume a WTP of £40,000/QALY is acceptable. It would not be unreasonable
to expect the price to be set to this level. Now let’s take the price of the new drug out
of the equation. Drug A has a cost/QALY of £15K and drug B £25k. The innovation of
drug A comes at a higher price than drug B. An alternative would be to fix the
innovative component at an additional £20k for example, up to a set maximum
threshold. Drug A plus innovation mark-up would be allowed to price to £35k and
drug B limited to the £40k maximum threshold.CONCLUSION:The efficiency of the
UK NHS will be compromised if, as proposed, multiple willingness to pay (WTP)
thresholds are implemented in the value based pricing (VBP) scheme for pharma-
ceuticals.
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OBJECTIVES: In recent years Health Technology Assessments (HTA) are increas-
ingly applied to healthcare decisions, involving a complex constellation of stake-
holders. Effective collaboration and communication with the HTA stakeholder
community requires a holistic understanding of this ecosystem. To better under-
stand multi-stakeholder influence dynamics across the HTA ecosystem, social net-
work analysis techniques were employed. METHODS: Information on 74 HTA
agencies was collected from various sources. Four data categories were included:
agencies, institutions, people (members) and technologies. For each category a
number of attributes were included (location, affiliations, memberships, type of
technology, decision on technology, etc.). The connections and types of connec-
tions between the datasets were added. The Ni3 software was applied to this data
to conduct the analysis and visualize HTA networks. RESULTS: The analysis en-
abled us to establish directions of influence (sources vs. absorbers: e.g., NICE vs.
AHTAPol) within a network, correlation between the level of connectivity and the
influence on market access, and also to observe HTA impact on the level of a drug
or therapeutic area. The tool enabled mapping of relationship links that represent
direction and weight of influence, overlaying displayed stakeholders with visual
charts summarizing sets of quantitative values (such as number of employees or
budget) for visual pattern matching and comparison, and geographic analysis.
CONCLUSIONS: The application of social network analysis allowed visualization of
the complex multi-stakeholder dynamics across HTA ecosystems to answer ques-
tions such as who are key influencers when it comes to coverage and reimburse-
ment decisions. Understanding the complexity of healthcare networks is key to
answering today’s business-relevant questions. Although this research was ex-
plorative in nature, it warrants further refinement by combining HTA expert net-
works with commonly available KOL networks, to further explore the connectivity
within the New Health ecosystem.
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OBJECTIVES: AHTAPol operates in Poland since 2005. Recommendations issued by
Consultative Council of AHTAPol are closely tracked as they support reimbursement
decision making. We aimed at evaluating of predictors for positive (supporting cover-
ing of costs from public budget) and negative recommendations of AHTAPol. In par-
ticular we wanted to see whether a threshold value for ICER (cost per QALY) can be
identified to drive AHTAPol decisions. METHODS: As only recommendations texts,
neither HTA reports nor critical appraisals, are publicly available on the official
website, two independent analysts have reviewed all recommendations issued
before January 28, 2011. Each recommendation was evaluated using predefined
criteria on decision rationales, i.e. whether negative or positive recommendations
were supported by arguments on clinical efficacy (with special interest on hard
endpoints defined according to Polish HTA guidelines), safety, cost-effectiveness,
budget impact and others. PPV, NPV, LR-and LRwere calculated for each criteria.
Although the content of recommendations is structured, not all could be assessed
based on each of the predefined criteria. Prediction model was developed for pos-
itive and negative recommendations. RESULTS: Two hundred eighty-five recom-
mendations were identified including 177 positive and 108 negative ones, which
were generally more elaborated. Clinical efficacy motivates recommendations
most often, but positive impact on hard endpoints was explicitly reported in 15
negative recommendations and lack of such proven efficacy in 38 positive recom-
mendations. Safety and cost-effectiveness were more often recalled in negative
than positive recommendations. Budget impact of novel technology was a weak
predictor of recommendation. No threshold value of QALY cost can be specified
based on recommendations. CONCLUSIONS: Decision making by Consultative
Council of AHTAPol is multi-dimensional and can be hardly predicted. Apart from
efficacy, negative recommendations are mainly driven by unfavorable safety and
cost-effectiveness.
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